Skip to main content

In Fed We Trust

In March, the market’s “fear gauge,” the VIX, reached 82.7, the highest close in its 30-year history. Daily moves in the S&P 500 averaged +/-5.0% and its 12.0% decline on March 16 was the worst day for the index since Black Monday in 1987. The New York Stock Exchange on March 23 closed the physical trading floor for the first time in its history and moved fully to electronic trading.

As headlines focused on the equity markets, the volatility in the fixed income markets was unrivaled. As investors looked to raise cash, dealers, who typically act as shock absorbers for the bond market, were not able to match panicked sellers with willing buyers. A lack of liquidity occurred in the fixed income market and extreme price dislocations occurred.

Issues were selling far below their intrinsic value. No segment of the bond market was left out, including Treasuries. Treasury yields collapsed in March to all-time lows and investment-grade credit spreads widened dramatically, experiencing an unprecedented 150 basis point move. Downgrades, especially in high-yield bonds, seemed unavoidable as the fear of “fallen angels” became reality. Extraordinary measures were required to stabilize the fixed income markets.

The Federal Reserve responded quickly, utilizing emergency rate cuts and unlimited quantitative easing. It slashed policy rates to near 0% and purchased treasuries, peaking at $75 billion per day, mortgage-backed securities, collateralized MBSs and agency MBSs. It established several swap lines to stem the heavy selling by foreign central banks that needed to raise cash.

In addition, the Fed announced a number of new targeted lending facilities to support commercial paper issuers, primary dealers and money market funds. It re-established the Term Asset Backed Securities Loan Facility to support credit to consumers and businesses. The Fed even agreed to purchase high-yield exchange traded funds and the fallen angels, or downgraded bonds issued by large corporations. It has essentially become the buyer of last resort for a broad spectrum of debt.

Altogether, the Fed has expanded or created nine lending programs and has agreed to provide up to $2.3 trillion in loans to entities that do not have ready access to the debt markets, including aid to states, cities and mid-small businesses. The Fed’s balance sheet has surpassed $6 trillion for the first time in its history. The Fed has clearly signaled it stands ready to do whatever is necessary to stave off a long-lasting recession.

If you have any questions, or would like to begin talking to a retirement plan advisor, please get in touch by calling (800) 388-1963 or email hbs@hanys.org.

Popular posts from this blog

SECURE 2.0 Discussion Series: Session Two

The retirement industry has been buzzing since the SECURE 2.0 Act was signed into law last December. This new, comprehensive legislation has sparked a lot of discussion. As with any major reform, it will take time for the industry to fully adapt and understand all its implications. Following our April 11 webinar on the first three months of the industry’s response, our team reconvened to discuss some of what we have heard from our client and vendor partners and to respond to some of the great questions we heard from attendees. Panel participants included the following HBS team members: Noah Buck, Christina Bauer-Dobias, Sean Bayne, Vincent Bocchinfuso and Kathleen Coonan. The Discussion SB – Throughout the webinar, I wanted to stress two things: 1) confusion about where to start and what is expected from plan sponsors is normal; and 2) even more than three months in, this is a developing situation and people should expect changes as time goes on. With those in mind, engagement through

SECURE 2.0 Discussion Series: Session One

SECURE 2.0 provisions: What we know and what’s still up in the air The SECURE 2.0 Act, signed into law in late December 2022, has factored heavily in retirement industry discourse since the final legislation was published. As with any legislation of this depth and breadth, there’s a lot to digest and the industry takes time to adjust. Our team of experienced advisors recently met to discuss some of the more nuanced provisions of the legislation, such as changes to Roth contributions, and what they could mean for plan sponsors. Panel participants included the following HBS team members: Noah Buck, Christina Bauer-Dobias, Sean Bayne, Vincent Bocchinfuso and Kathleen Coonan. Highlights of our panel’s conversation below should serve to help guide plan sponsor thinking. On Roth employer contributions NB – In addition to deferring pre-tax or Roth, plan sponsors can now allow employer contributions to be classified as Roth, is that right? VB – Correct. This is immediately available to plan s

What you should know about biosimilars

Rapidly increasing healthcare costs will likely continue to impact employers for the foreseeable future. As a result, many employers are considering strategies to manage these costs, including rising prescription drug costs. The introduction of biosimilar drugs as an alternative to biologics may bring value to healthcare by offering cost savings and increasing employee access to necessary medications. While biosimilars can potentially combat rising prescription drug costs, employers will need to learn more about them before considering how their health plans can accommodate these newer drugs. This article explores biosimilar drugs and ways employers can promote or manage their use. What are biosimilars? The European Medicines Agency defines a biosimilar as “a biological medicine highly similar to another already approved biological medicine.” It is produced from living organisms — humans, animals or microorganisms, meaning they aren’t created from synthesized chemicals. They are also